<DOC>
	<DOC>NCT01047540</DOC>
	<brief_summary>The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes</brief_summary>
	<brief_title>Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult, Immunocompetent men and women in good health of any ethnic group History of recurrent episodes of genital herpes for at least 12 months Seropositive for Herpes Simplex Virus HSV Type 2 Body Mass Index (BMI) between 18 and 35 kg/m2 Present episode of genital herpes Intake of systemic drug against HSV or any topical application against HSV within 7 days before randomization for the trial Intake of systemic corticosteroids, other immunomodulating agents or any investigational agent within 3 months before randomization for the trial Positive results in any of the virology tests for human immunodeficiency virus antibody (HIVAb), hepatitis C antibody (HCVAb), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>